| Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival … SEM Herman, AL Gordon, AJ Wagner, NA Heerema, W Zhao, JM Flynn, ... Blood, The Journal of the American Society of Hematology 116 (12), 2078-2088, 2010 | 738 | 2010 |
| Phase II trial of sorafenib in metastatic thyroid cancer RT Kloos, MD Ringel, MV Knopp, NC Hall, M King, R Stevens, J Liang, ... Journal of Clinical Oncology 27 (10), 1675-1684, 2009 | 669 | 2009 |
| Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer ET Lam, MD Ringel, RT Kloos, TW Prior, MV Knopp, J Liang, S Sammet, ... Journal of Clinical Oncology 28 (14), 2323-2330, 2010 | 431 | 2010 |
| Short-term outcome of endoscopic versus microscopic pituitary adenoma surgery: a systematic review and meta-analysis M Ammirati, L Wei, I Ciric Journal of Neurology, Neurosurgery & Psychiatry 84 (8), 843-849, 2013 | 353 | 2013 |
| Amide proton transfer MR imaging of prostate cancer: a preliminary study G Jia, R Abaza, JAD Williams, DL Zynger, J Zhou, ZK Shah, M Patel, ... Journal of Magnetic Resonance Imaging 33 (3), 647-654, 2011 | 211 | 2011 |
| A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma K Maddocks, B Christian, S Jaglowski, J Flynn, JA Jones, P Porcu, L Wei, ... Blood, The Journal of the American Society of Hematology 125 (2), 242-248, 2015 | 163 | 2015 |
| A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas T Bekaii-Saab, J Markowitz, N Prescott, W Sadee, N Heerema, L Wei, ... Clinical Cancer Research 15 (18), 5895-5901, 2009 | 142 | 2009 |
| Prostate cancer incidence in males with Lynch syndrome S Haraldsdottir, H Hampel, L Wei, C Wu, W Frankel, T Bekaii-Saab, ... Genetics in medicine 16 (7), 553-557, 2014 | 135 | 2014 |
| Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non–small-cell lung cancer DH Owen, L Wei, EM Bertino, T Edd, MA Villalona-Calero, K He, ... Clinical Lung Cancer 19 (6), e893-e900, 2018 | 133 | 2018 |
| Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease J Markowitz, TR Brooks, MC Duggan, BK Paul, X Pan, L Wei, Z Abrams, ... Cancer Immunology, Immunotherapy 64, 149-159, 2015 | 131 | 2015 |
| HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib J Peck, L Wei, M Zalupski, B O’Neil, M Villalona Calero, T Bekaii-Saab Oncology 82 (3), 175-179, 2012 | 112 | 2012 |
| Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. MH Shah, L Wei, LJ Wirth, GA Daniels, JA De Souza, CD Timmers, ... Journal of Clinical Oncology 35 (15_suppl), 6022-6022, 2017 | 94 | 2017 |
| Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma NC Dunavin, L Wei, P Elder, GS Phillips, DM Benson Jr, CC Hofmeister, ... Leukemia & lymphoma 54 (8), 1658-1664, 2013 | 91 | 2013 |
| Quality of life outcomes of transoral robotic surgery with or without adjuvant therapy for oropharyngeal cancer R Sethia, AC Yumusakhuylu, I Ozbay, V Diavolitsis, NV Brown, S Zhao, ... The Laryngoscope 128 (2), 403-411, 2018 | 90 | 2018 |
| HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma Y Hou, H Nitta, L Wei, PM Banks, B Portier, AV Parwani, Z Li Breast cancer research and treatment 166, 447-457, 2017 | 85 | 2017 |
| PD‐L1 expression and CD8‐positive T cells are associated with favorable survival in HER2‐positive invasive breast cancer Y Hou, H Nitta, L Wei, PM Banks, M Lustberg, R Wesolowski, ... The breast journal 24 (6), 911-919, 2018 | 81 | 2018 |
| Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer DH Ahn, J Li, L Wei, A Doyle, JL Marshall, LJ Schaaf, MA Phelps, ... Scientific reports 5 (1), 12122, 2015 | 77 | 2015 |
| Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2 … NL Busaidy, B Konda, L Wei, LJ Wirth, C Devine, GA Daniels, ... Thyroid 32 (10), 1184-1192, 2022 | 70 | 2022 |
| Phase 2 study of ibrutinib in classic and variant hairy cell leukemia KA Rogers, LA Andritsos, L Wei, EM McLaughlin, AS Ruppert, ... Blood, The Journal of the American Society of Hematology 137 (25), 3473-3483, 2021 | 65 | 2021 |
| A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma VP Grignol, T Olencki, K Relekar, C Taylor, A Kibler, C Kefauver, L Wei, ... Journal of immunotherapy 34 (6), 509-515, 2011 | 62 | 2011 |
